A major new review has put hundreds of alternative autism treatments under the microscope—and most didn’t hold up. Scientists ...
The FDA has cleared LumosityRx to improve attention function in adults aged 22 to 55 years with primarily inattentive or combined-type ADHD.
There is no scientific evidence base for routine use of multiple psychiatric drugs, particularly for children.
The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
Erie County Treatment Court held its 50th graduation ceremony, celebrating 15 new graduates with keynote speaker Pennsylvania Supreme Court Justice Debra Todd. The court is partnering with Erie County ...
Lumos Labs has obtained a clearance from the FDA for its popular Lumosity brain training platform, greenlighting a version of it to be marketed as a prescription ...
The number of people in Ontario who were prescribed stimulants to treat attention deficit hyperactivity disorder skyrocketed more than 150 per cent between 2015 and 2023, a new study has found, with ...
Abstract: This systematic literature review examines the efficacy of gamification in neurofeedback (NF) therapy approaches for the treatment of Attention-Deficit ...
An experimental study of individuals with ADHD revealed that those with increased gyrification in frontal cortical regions of the brain generally responded better to treatment. The treatment was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback